Maternal serum soluble fms-like tyrosine kinase-1 at 22 and 32 weeks in the prediction of pre-eclampsia

Ultrasound in Obstetrics and Gynecology

Volumn 47, Issue 6, 2016, Pages 755-761

  Wright, D ^a   Krajewska, K ^b   Bogdanova, A ^b   Wright, A ^a   Nicolaides, K H ^b  

^a UNIVERSITY OF EXETER   (United Kingdom)

^b KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

pre eclampsia; repeat measurements; soluble fms like tyrosine kinase 1; third trimester screening

Indexed keywords

BIOLOGICAL MARKER; FLT1 PROTEIN, HUMAN; VASCULOTROPIN RECEPTOR 1;

ADULT; BLOOD; EARLY DIAGNOSIS; FEMALE; HUMAN; METABOLISM; PRE-ECLAMPSIA; PREDICTIVE VALUE; PREGNANCY; SECOND TRIMESTER PREGNANCY; SENSITIVITY AND SPECIFICITY; THIRD TRIMESTER PREGNANCY;

ADULT; BIOMARKERS; EARLY DIAGNOSIS; FEMALE; HUMANS; PRE-ECLAMPSIA; PREDICTIVE VALUE OF TESTS; PREGNANCY; PREGNANCY TRIMESTER, SECOND; PREGNANCY TRIMESTER, THIRD; SENSITIVITY AND SPECIFICITY; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 84971538964     PISSN: 09607692     EISSN: 14690705     Source Type: Journal    
DOI: 10.1002/uog.15850     Document Type: Article

References (28)

1. Maynard SE, Min JY, Merchan J, Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, Libermann TA, Morgan JP, Sellke FW, Stillman IE, Epstein FH, Sukhatme VP, Karumanchi SA,. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003; 111: 649-658.
2. Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, Schisterman EF, Thadhani R, Sachs BP, Epstein FH, Sibai BM, Sukhatme VP, Karumanchi SA,. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004; 350: 672-683.
3. Kim NK, Lee DS, Jeong DH, Sung MS, Kim KT,. The relationship of the level of circulating antiangiogenic factors to the clinical manifestations of preeclampsia. Prenat Diagn 2009; 29: 464-470.
4. Chaiworapongsa T, Romero R, Savasan ZA, Kusanovic JP, Ogge G, Soto E, Dong Z, Tarca A, Gaurav B, Hassan SS,. Maternal plasma concentrations of angiogenic/anti-angiogenic factors are of prognostic value in patients presenting to the obstetrical triage area with the suspicion of preeclampsia. J Matern Fetal Neonatal Med 2011; 24: 1187-207.
5. Verlohren S, Herraiz I, Lapaire O, Schlembach D, Moertl M, Zeisler H, Calda P, Holzgreve W, Galindo A, Engels T, Denk B, Stepan H,. The sFlt-1/PlGF ratio in different types of hypertensive pregnancy disorders and its prognostic potential in preeclamptic patients. Am J Obstet Gynecol 2012; 206: 58.e1-8.
6. Lai J, Garcia-Tizon Larroca S, Peeva G, Poon LC, Wright D, Nicolaides KH,. Competing risks model in screening for preeclampsia by serum placental growth factor and soluble fms-like tyrosine kinase-1 at 30-33 weeks' gestation. Fetal Diagn Ther 2014; 35: 240-248.
7. Kleinrouweler C, Wiegerinck M, Ris-Stalpers C, Bossuyt P, van der Post J, von Dadelszen P, Mol B, Pajkrt E, for the EBM CONNECT Collaboration. Accuracy of circulating placental growth factor, vascular endothelial growth factor, soluble fms-like tyrosine kinase 1 and soluble endoglin in the prediction of pre-eclampsia: a systematic review and meta-analysis. BJOG 2012; 119: 778-787.
8. Gallo DM, Wright D, Casanova C, Campanero M, Nicolaides KH,. Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 19-24 weeks' gestation. Am J Obstet Gynecol 2015. pii: S0002-9378(15)02345-5. doi: 10.1016/j.ajog.2015.11.016. [Epub ahead of print].
9. Garcia-Tizon Larroca S, Tayyar A, Poon LC, Wright D, Nicolaides KH,. Competing risks model in screening for preeclampsia by biophysical and biochemical markers at 30-33 weeks' gestation. Fetal Diagn Ther 2014; 36: 9-17.
10. Tsiakkas A, Saiid Y, Wright A, Wright D, Nicolaides KH,. Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 30-34 weeks' gestation. Am J Obstet Gynecol 2016. pii: S0002-9378(16)00300-8. doi: 10.1016/j.ajog.2016.02.016. [Epub ahead of print].
11. Wright D, Bradbury I,. Repeated measures screening for Down's Syndrome. BJOG 2005; 112: 80-83.
12. Wright D, Bradbury I, Malone F, D'Alton M, Summers A, Huang T, Ball S, Baker A, Nix B, Aitken D, Crossley J, Cuckle H, Spencer K,. Cross-trimester repeated measures testing for Down's syndrome screening: an assessment. Health Technol Assess 2010; 14: 1-80.
13. Wright D, Syngelaki A, Akolekar R, Poon LC, Nicolaides KH,. Competing risks model in screening for preeclampsia by maternal characteristics and medical history. Am J Obstet Gynecol 2015; 213: 62.e1-10.
14. Robinson HP, Fleming JE,. A critical evaluation of sonar crown-rump length measurements. Br J Obstet Gynaecol 1975; 82: 702-710.
15. Snijders RJ, Nicolaides KH,. Fetal biometry at 14-40 weeks' gestation. Ultrasound Obstet Gynecol 1994; 4: 34-48.
16. Brown MA, Lindheimer MD, de Swiet M, Van Assche A, Moutquin JM,. The classification and diagnosis of the hypertensive disorders of pregnancy: Statement from the international society for the study of hypertension in pregnancy (ISSHP). Hypertens Pregnancy 2001; 20: IX-XIV.
17. Tsiakkas A, Duvdevani N, Wright A, Wright D, Nicolaides KH,. Serum soluble fms-like tyrosine kinase-1 in the three trimesters of pregnancy: effects of maternal characteristics and medical history. Ultrasound Obstet Gynecol 2015; 45: 584-590.
18. R Development Core Team. R. A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. 2011; ISBN 3-900051-07-0, http://www.R-project.org/.
19. Therneau T,. A Package for Survival Analysis in S. R package version 2.37-7, 2014; http://CRAN.R-project.org/package=survival.
20. Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez J, Müller M,. pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics 2011; 12: 77-84.
21. Tsiakkas A, Mendez O, Wright A, Wright D, Nicolaides KH,. Maternal serum soluble fms-like tyrosine kinase-1 at 12, 22, 32 and 36 weeks' gestation in screening for pre-eclampsia. Ultrasound Obstet Gynecol 2016; 47: 478-483.
22. Nicolaides KH,. Turning the pyramid of prenatal care. Fetal Diagn Ther 2011; 29: 183-196.
23. Bujold E, Roberge S, Lacasse Y, Bureau M, Audibert F, Marcoux S, Forest JC, Giguère Y,. Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis. Obstet Gynecol 2010; 116: 402-414.
24. Roberge S, Nicolaides K, Demers S, Villa P, Bujold E,. Prevention of perinatal death and adverse perinatal outcome using low-dose aspirin: a meta-analysis. Ultrasound Obstet Gynecol 2013; 41: 491-499.
25. Koopmans CM, Bijlenga D, Groen H, Vijgen SM, Aarnoudse JG, Bekedam DJ, van den Berg PP, de Boer K, Burggraaff JM, Bloemenkamp KW, Drogtrop AP, Franx A, de Groot CJ, Huisjes AJ, Kwee A, van Loon AJ, Lub A, Papatsonis DN, van der Post JA, Roumen FJ, Scheepers HC, Willekes C, Mol BW, van Pampus MG,; HYPITAT study group. Induction of labour versus expectant monitoring for gestational hypertension or mild pre-eclampsia after 36 weeks' gestation (HYPITAT): a multicentre, open-label randomised controlled trial. Lancet 2009; 374: 979-988.
26. Kumasawa K, Ikawa M, Kidoya H, Hasuwa H, Saito-Fujita T, Morioka Y, Takakura N, Kimura T, Okabe M,. Pravastatin induces placental growth factor (PGF) and ameliorates preeclampsia in a mouse model. Proc Natl Acad Sci USA 2011; 108: 1451-1455.
27. Li Z, Zhang Y, Ying Ma J, Kapoun AM, Shao Q, Kerr I, Lam A, O'Young G, Sannajust F, Stathis P, Schreiner G, Karumanchi SA, Protter AA, Pollitt NS,. Recombinant vascular endothelial growth factor 121 attenuates hypertension and improves kidney damage in a rat model of preeclampsia. Hypertension 2007; 50: 686-692.
28. Thadhani R, Kisner T, Hagmann H, Bossung V, Noack S, Schaarschmidt W, Jank A, Kribs A, Cornely OA, Kreyssig C, Hemphill L, Rigby AC, Khedkar S, Lindner TH, Mallmann P, Stepan H, Karumanchi SA, Benzing T,. Pilot study of extracorporeal removal of soluble fms-like tyrosine kinase 1 in preeclampsia. Circulation 2011; 124: 940-950.